HIV PREVENTIVE VACCINE BASED ON HIV-SPECIFIC ANTIBODIES

摘要

1. A method of obtaining an HIV vaccine that prevents the development of infection by immunizing uninfected people, comprising the steps of:! i) creation of a phagemid library of monoclonal antibodies, the sequences of which are contained in mRNA of B-lymphocytes obtained from several patients infected with HIV-1 subtype A or B,! ii) enrichment of the phagemid antibody library with panning on native or recombinant HIV-1 peptides,! iii) collection of HIV-1 peptide / polypeptide / protein material by reverse panning using an HIV-1 specific phagemid library mounted on a solid support! iv) identification and quantification of the peptide material obtained in step iii) and its variability using mass spectrometric (PEAKS-LC-MS) analysis and! (v) using the results of the analysis of step iv) to obtain glycosylated recombinant HIV-1 env peptides in an inducible expression system with eukaryotic glycosylation (Leishmania tarentolae, yeast),! (vi) purification of recombinant HIV-1 env peptides and preparation of an immunoactivating composition for vaccination using a suitable adjuvant as a delivery system (sterically stabilized liposomes, virosomes). ! 2. The method according to claim 1, wherein the HIV carriers used to produce the biomaterial are infected with HIV of one or different subtypes. ! 3. The method according to claim 1, in which HIV-infected to obtain viral material can be both untreated and treated with antiretroviral drugs. ! 4. The method according to claim 1, when the resulting viral material of a cohort of HIV-infected multiplies as a pool (many